Drug survival of apremilast in patients treated for psoriasis in a real-world setting

被引：19
|
作者：
Lee, Erica B. [1 ]
Amin, Mina [2 ,4 ]
Wu, Jashin J. [3 ]
机构：
[1] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA
[2] Univ Calif Riverside, Sch Med, Riverside, CA 92521 USA
[3] Kaiser Permanente Los Angeles, Dept Dermatol, Med Ctr, 1515 North Vermont Ave,5th Floor, Los Angeles, CA 90027 USA
[4] Kaiser Permanente Los Angeles, Dept Med, Med Ctr, Los Angeles, CA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2018年 / 79卷 / 04期
关键词：
ORAL PHOSPHODIESTERASE-4 INHIBITOR; SEVERE PLAQUE PSORIASIS; CONTROLLED-TRIAL; PHASE-III; EFFICACY; MODERATE; SAFETY;
D O I：
10.1016/j.jaad.2018.03.028
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：760 / 761
页数：3
相关论文
共 50 条
  • [1] Comment on "Drug survival of apremilast for psoriasis in a real-world setting"
    Santos-Juanes, Jorge
    Velasco, Lucia
    Munguia-Calzada, Pablo
    Lozano, Ana
    Gomez-Diez, Santiago
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (04) : E83 - E84
  • [2] Repy to: "Comment on 'Drug survival of apremilast for psoriasis in a real-world setting'"
    Lee, Erica B.
    Amin, Mina
    Wu, Jashin J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (04) : E85 - E85
  • [3] Drug survival of apremilast in a real-world setting
    Kishimoto, Megumi
    Komine, Mayumi
    Kamiya, Koji
    Sugai, Junichi
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2019, 46 (07): : 615 - 617
  • [4] Drug survival of secukinumab for psoriasis in a real-world setting
    Lee, Erica B.
    Amin, Mina
    Egeberg, Alexander
    Wu, Jashin J.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (02) : 150 - 151
  • [5] Real-world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center
    Zeb, Lawangeen
    Mhaskar, Rahul
    Lewis, Suzanna
    Patel, Nishit S.
    Sadhwani, Divya
    Patel, Nupur
    Ekhlassi, Erfon
    Lu, Yuanyuan
    Seminario-Vidal, Lucia
    DERMATOLOGIC THERAPY, 2021, 34 (02)
  • [6] Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real-world setting
    Kapniari, Eirini
    Dalamaga, Maria
    Papadavid, Evangelia
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [7] Drug survival of brodalumab is greater in patients with psoriasis and psoriatic arthritis in a real-world setting
    Gkanti, Vasiliki
    Dalamaga, Maria
    Papadavid, Evangelia
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2023, 62 (01) : E31 - E34
  • [8] Real-world use of apremilast for patients with psoriasis in Japan
    Kishimoto, Megumi
    Komine, Mayumi
    Hioki, Tomoyuki
    Kamiya, Koji
    Sugai, Junichi
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2018, 45 (11): : 1345 - 1348
  • [9] Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience
    Distel, Julian
    Cazzaniga, Simone
    Seyed Jafari, S. Morteza
    Emelianov, Vladimir
    Schlapbach, Christoph
    Yawalkar, Nikhil
    Heidemeyer, Kristine
    DERMATOLOGY, 2022, 238 (02) : 267 - 275
  • [10] Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis
    Phan, Celine
    Beneton, Nathalie
    Delaunay, Juliette
    Reguiai, Ziad
    Boulard, Claire
    Fougerousse, Anne-Claire
    Cinotti, Elisa
    Romanelli, Marco
    Mery-Bossard, Laure
    Thomas-Beaulieu, Domitille
    Parier, Josiane
    Maccari, Francois
    Chaby, Guillaume
    Bastien, Marie
    Begon, Edouard
    Samimi, Mahtab
    Prignano, Francesca
    Beauchet, Alain
    Mahe, Emmanuel
    DRUGS & AGING, 2020, 37 (09) : 657 - 663
12345